4040894
Last Update Posted: 2024-06-20
Recruiting status is unknown
All Genders accepted | 18 Years + |
Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
This is an expanded access protocol intended to provide access to teprotumumab for the treatment of up to 60 patients in the United States with active moderate to severe thyroid eye disease where there is no comparable or satisfactory alternative therapy for treatment.
Requests for access to the Sponsor must be made by a licensed physician for a specific patient, based on a determination with the patient that the benefits of treatment with the investigational drug outweigh the risks. Licensed physician's with eligible patients must apply and meet requirements for participation in the expanded access program.
Study acquired from Horizon in 2024.
Eligibility
Relevant conditions:
Thyroid Eye Disease
Graves' Orbitopathy
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov